Literature DB >> 28067871

Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.

E McDuffee1, G Aue1, L Cook1, C Ramos-Delgado1, R Shalabi1, T Worthy1, P Vo1, R W Childs1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28067871      PMCID： PMC9069644          DOI： 10.1038/bmt.2016.346

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  12 in total

1.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Authors:  Philippe Armand; Margaret A Shipp; Vincent Ribrag; Jean-Marie Michot; Pier Luigi Zinzani; John Kuruvilla; Ellen S Snyder; Alejandro D Ricart; Arun Balakumaran; Shelonitda Rose; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

2.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

3.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

4.  Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Authors:  L Angenendt; C Schliemann; M Lutz; E Rebber; A B Schulze; M Weckesser; L Stegger; M Schäfers; C Groth; T Kessler; G Lenz; M Stelljes; W E Berdel
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

5.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

6.  PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

Authors:  Ryo Yamamoto; Momoko Nishikori; Toshio Kitawaki; Tomomi Sakai; Masakatsu Hishizawa; Masaharu Tashima; Tadakazu Kondo; Katsuyuki Ohmori; Masayuki Kurata; Takamasa Hayashi; Takashi Uchiyama
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

7.  Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.

Authors:  R Srinivasan; S Chakrabarti; T Walsh; T Igarashi; Y Takahashi; D Kleiner; T Donohue; R Shalabi; C Carvallo; A J Barrett; N Geller; R Childs
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

8.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Authors:  Asim Saha; Kazutoshi Aoyama; Patricia A Taylor; Brent H Koehn; Rachelle G Veenstra; Angela Panoskaltsis-Mortari; David H Munn; William J Murphy; Miyuki Azuma; Hideo Yagita; Brian T Fife; Mohammed H Sayegh; Nader Najafian; Gerard Socie; Rafi Ahmed; Gordon J Freeman; Arlene H Sharpe; Bruce R Blazar
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

9.  Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective.

Authors:  Jose Caetano Villasboas; Stephen M Ansell; Thomas E Witzig
Journal:  Oncotarget       Date:  2016-03-15

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  9 in total

Review 1.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

2.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

Review 3.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 4.  Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.

Authors:  Sabela Bobillo; Juan Camilo Nieto; Pere Barba
Journal:  Bone Marrow Transplant       Date:  2021-03-19       Impact factor: 5.174

5.  Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Authors:  Sun Yao; Chen Jianlin; Qiao Zhuoqing; Li Yuhang; Hu Jiangwei; Hu Guoliang; Ning Hongmei; Zhang Bin; Hu Liangding
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

6.  Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.

Authors:  Lambros Kordelas; Ulrike Buttkereit; Falko M Heinemann; Peter A Horn; Bernd Giebel; Dietrich W Beelen; H Christian Reinhardt; Vera Rebmann
Journal:  Front Immunol       Date:  2021-09-24       Impact factor: 7.561

Review 7.  Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.

Authors:  Elham Roshandel; Farzaneh Tavakoli; Sayeh Parkhideh; Sedigheh Sadat Akhlaghi; Maria Tavakoli Ardakani; Masoud Soleimani
Journal:  Health Sci Rep       Date:  2022-03-08

Review 8.  Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.

Authors:  Pier Edoardo Rovatti; Valentina Gambacorta; Francesca Lorentino; Fabio Ciceri; Luca Vago
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

Review 9.  Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

Authors:  Laura Jimbu; Oana Mesaros; Cristian Popescu; Alexandra Neaga; Iulia Berceanu; Delia Dima; Mihaela Gaman; Mihnea Zdrenghea
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.